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ABSTRACT  26 
Chlamydia trachomatis infection is the most prevalent bacterial sexually transmitted 27 
infection and can cause significant reproductive morbidity in women. There is 28 
insufficient knowledge of C. trachomatis-specific immune responses in humans, which 29 
could be important in guiding vaccine development efforts. In contrast, murine models 30 
have clearly demonstrated the essential role of Type 1 T helper cells (Th1), especially 31 
interferon-gamma (IFN-γ) producing CD4+ T-cells, in protective immunity to chlamydia. 32 
To determine the frequency and magnitude of Th1 cytokine responses elicited to C. 33 
trachomatis infection in humans, we stimulated peripheral blood mononuclear cells from 34 
90 chlamydia-infected women with C. trachomatis elementary bodies, Pgp3, and major 35 
outer membrane protein and measured IFN-γ-, tumor necrosis factor-alpha (TNF-α)-, 36 
and interleukin 2 (IL-2)-producing CD4+ and CD8+ T-cell responses using intracellular 37 
cytokine staining. The majority of chlamydia-infected women elicited CD4+ TNF-α 38 
responses, with frequency and magnitude varying significantly depending on the C. 39 
trachomatis antigen used. CD4+ IFN-γ and IL-2 responses occurred infrequently, as did 40 
production of any of the three cytokines by CD8+ T-cells. About one-third of TNF-α-41 
producing CD4+ T-cells co-produced IFN-γ or IL-2. In summary, the predominant Th1 42 
cytokine response elicited to C. trachomatis infection in women was a CD4+ TNF-α 43 
response, not CD4+ IFN-γ, and a subset of the CD4+ TNF-α-positive cells produced a 44 
second Th1 cytokine. 45 
46 
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INTRODUCTION  47 
Chlamydia trachomatis, an obligate intracellular bacterium, causes mucosal infection 48 
(chlamydia) of the genital, anorectal, and oropharyngeal surfaces in humans. Chlamydia 49 
is the most prevalent bacterial sexually transmitted infection (STI) worldwide (1), and 50 
genital chlamydia is associated with significant reproductive morbidity, including tubal 51 
factor infertility. Despite over two decades of national screening efforts in the U.S., the 52 
prevalence of chlamydia continues to rise (2). Availability of a chlamydia vaccine could 53 
improve chlamydia prevention efforts (3, 4), but vaccine development efforts have been 54 
hindered in part by insufficient knowledge of the immune responses to C. trachomatis 55 
infection in humans that contribute to protective immunity (5).  56 
Because of the ethical concerns in performing Chlamydia challenge or natural 57 
history studies in humans, animal models have played a critical role in identifying the 58 
mechanisms of protective immunity to chlamydia (6).  In murine models of genital 59 
chlamydia, protective immunity is largely mediated through CD4+ T helper type 1 (Th1) 60 
cell responses, with interferon-gamma (IFN-γ) playing an essential role (7). Another Th1 61 
cytokine, tumor necrosis factor alpha (TNF-α), has also been implicated in protective 62 
immunity to chlamydia in murine studies (8-10). TNF-α is a pleiotropic proinflammatory 63 
cytokine released from monocytes, macrophages, and lymphocytes that stimulates a 64 
cascade of other cytokines (11). In the murine chlamydia model, the influence of TNF-α 65 
on chlamydia clearance appears to be specific to the mucosal site infected. For 66 
example, in the mouse pneumonitis model (which uses C. muridarum), TNF-α deletion 67 
significantly accelerates mortality and increases organism burden in the lung (8, 9), 68 
suggesting a protective role for TNF-α. However, TNF-α depletion seems to have no 69 
effect on C. muridarum clearance from the genital tract (12-14), although its expression 70 
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in the genital tract increases within days of chlamydia infection (12, 15), suggesting 71 
TNF-α alone is not sufficient for chlamydia clearance. Interestingly, several studies 72 
demonstrate TNF-α may exert its effects in synergy with other cytokines (16) or 73 
interleukins (17). One murine study demonstrated that CD4+ T-cells producing both IFN-74 
γ and TNF-α correlated with protection against chlamydia challenge (16). While the role 75 
of TNF-α in mediating protective immunity remains unclear, murine studies have 76 
reported this proinflammatory cytokine may contribute to upper genital tract pathology 77 
(13).  78 
Translating immune mechanisms of chlamydia protection from animal studies to 79 
humans is difficult, as mechanisms can differ by animal model (7, 18). For example, 80 
mice deficient in CD8+ T-cells still resolve primary infection (7, 19), yet a non-human 81 
primate model demonstrated a key role for CD8+ T-cells in mediating protection against 82 
chlamydia (20). The dominant mucosal mononuclear cell type response to chlamydia 83 
also differs by species with CD4+ T-cells being more numerous in the genital tract in 84 
mice (21) and CD8+ T-cells in the non-human primate trachoma model (22). 85 
Additionally, differences in Chlamydia species tested, time to infection clearance, 86 
estrous cycle duration, and variable susceptibility to upper genital tract infection make 87 
correlation to humans difficult (7, 18). In humans, evidence for protective immunity to 88 
chlamydia is mainly based on epidemiological studies, which have shown that a history 89 
of prior chlamydia, spontaneous resolution of chlamydia, and persons with a high 90 
likelihood of repeated chlamydia exposures (e.g., commercial sex workers) are 91 
associated with a lower reinfection risk (23-25). Although immune mechanisms that 92 
mediate protection against C. trachomatis in humans remain to be fully elucidated, 93 
sparse evidence from two prospective human studies that measured C. trachomatis-94 
specific IFN-γ production by ELISA or ELISpot revealed IFN-γ was associated with 95 
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protective immunity (26, 27).   96 
To advance our understanding of C. trachomatis-specific immune mechanisms that 97 
contribute to protective immunity in humans, a more in depth evaluation of the C. 98 
trachomatis-specific T-cell effector responses and T-cell phenotypes is needed. To 99 
address this knowledge gap, we have established a cohort of chlamydia-infected 100 
women from which we have characterized clinical manifestations and are conducting 101 
immunological experiments to help unravel the key C. trachomatis-specific immune 102 
mechanisms and their contribution to protective immunity. Here, we present findings 103 
from our initial investigation of the C. trachomatis-specific Th1 cytokine responses (IFN-104 
γ, TNF-α, and IL-2) in chlamydia-infected women prior to treatment using intracellular 105 
cytokine staining.  106 
 107 
MATERIALS AND METHODS 108 
Study Population and Procedures. The study population was comprised of females 109 
≥16 years of age who presented to the Jefferson County Department of Health (JCDH) 110 
STD Clinic in Birmingham, Alabama, USA for treatment of a recent positive C. 111 
trachomatis screening nucleic acid amplification test (Hologic Aptima Combo 2 ® [AC2]; 112 
Hologic, Inc., Marlborough, MA). Patients did not receive empiric chlamydia therapy at 113 
the time of screening because they had no cervicitis findings and no other chlamydia 114 
treatment indications. Patients interested in the study provided written consent and were 115 
enrolled. Women who were pregnant, had a prior hysterectomy, were co-infected with 116 
HIV, syphilis, or gonorrhea (tested at screening), were immunosuppressed, or had 117 
received antibiotics with anti-chlamydial activity in the prior 30 days were excluded. 118 
     At enrollment, participants were interviewed and demographical, clinical, and 119 
behavioral data were collected. A pelvic examination was performed in which a vaginal 120 
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swab specimen was collected for wet mount microscopy and an endocervical swab 121 
specimen for chlamydia and gonorrhea testing by the AC2 per the manufacturer’s 122 
instructions. Blood was collected for isolation of peripheral blood mononuclear cells 123 
(PBMCs). All participants received directly observed therapy with azithromycin 1g and 124 
were advised to refer all sexual partners for treatment, if not already treated. PBMCs 125 
from five healthy, low-risk C. trachomatis-seronegative women (tested with a C. 126 
trachomatis elementary body-based ELISA assay [28]) without a history of chlamydia 127 
were used as negative controls. The study was approved by the University of Alabama 128 
at Birmingham (UAB) Institutional Review Board and JCDH.   129 
PBMC Isolation. At the UAB Center for Clinical and Translational Sciences 130 
Specimen Processing and Analytical Nexus, PBMCs were isolated from blood by 131 
centrifugation through lymphocyte separation medium (Mediatech, Inc, Manassas, VA). 132 
Upon isolation, cells were counted and examined for viability. PBMCs were frozen in 133 
1mL aliquots in 90% FBS+10% DMSO and cryopreserved in liquid nitrogen until used 134 
for immunological studies. 135 
Intracellular Cytokine Staining (ICS).  PBMCs were stimulated with C. trachomatis 136 
antigens and analyzed for cytokines as previously reported with modifications (29). 137 
Briefly, 2.5x105 cells were incubated for two hours at 37°C with 5% CO2 in RPMI-10 138 
media (RPMI 1640 medium containing 10% human AB serum, penicillin/streptomycin 139 
[50 U/mL], HEPES [25 mM] and L-glutamine [2mM]) in the presence of co-stimulatory 140 
antibodies CD28 and CD49d (BD Biosciences, San Diego, CA) and antigen, followed by 141 
a five-hour incubation in the presence of Brefeldin A and Monensin (both from BD 142 
Biosciences, San Diego, CA). Antigens used were: recombinant C. trachomatis Pgp3 (5 143 
µg/ml)  (Biorbyt, San Francisco, CA), pooled Major Outer Membrane Protein (MOMP) 144 
peptides (5 µg/ml)  (VS1 75-92, VS2 132-151, VS2 145-163, VS4 300-318, VS4 308-145 
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324; UAB Peptide Core, Birmingham, AL), formalin-fixed C. trachomatis elementary 146 
bodies (4 µg/ml) (EBs, pooled serotypes D, F and J; obtained from Dr. Richard Morrison 147 
from the University of Arkansas for Medical Sciences, Little Rock, AR), and 148 
Staphylococcus enterotoxin B (10 µg/ml) (SEB, Toxin Technologies, Carasota, FL) as 149 
the positive control. RPMI-10 supplemented with anti-CD28 and anti-CD49d antibodies, 150 
but without antigen, was used to determine background T-cell responses. Cells were 151 
subsequently labeled with LIVE/DEAD fluorescent reactive dye (Life Technologies, 152 
Eugene, OR), stained with surface antibodies against CD3-Pacific Blue (BD 153 
biosciences, San Diego, CA), CD4-Qdot 655, and CD8-Qdot 605 (both from Invitrogen, 154 
Carlsbad, CA), fixed and permeabilized (Cytofix/Cytoperm, BD Biosciences, San Diego, 155 
CA), and stained with antibodies for intracellular cytokines IFN-γ-Alexa 700, TNF-α-PE-156 
Cy7, and IL-2-PE (all from BD Biosciences, San Diego, CA). Approximately 100,000 157 
events were acquired on a LSRII (BD Immunocytometry Systems, San Diego, CA) and 158 
data was analyzed using FlowJo software (v9.8.5, TreeStar, Ashland, OR). All 159 
responses are reported after subtracting the background responses (media + co-160 
stimulatory antibodies).  161 
Statistical analysis.  Analyses were performed with SAS software, version 9.3 162 
(SAS Institute, Cary, NC). Descriptive statistics were used to summarize demographical 163 
and clinical characteristics. We evaluated quantitative and qualitative differences in 164 
cytokine responses, the latter to allow comparison with prior studies (26-27); cytokine 165 
responses >0.05% and twice the background response (media + co-stimulatory 166 
antibodies) were considered positive for our qualitative analyses. Differences in 167 
frequencies of each CD4+ cytokine response and each CD8+ cytokine response were 168 
evaluated by McNemar’s chi-square test. Differences in frequency of a specific cytokine 169 
response based on C. trachomatis antigen used for the stimulation were also evaluated 170 
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by McNemar’s chi-square test. Differences in the magnitude of CD4+ TNF-α responses 171 
(enumeration of cytokine-producing cells) by C. trachomatis antigen were evaluated 172 
with the Friedman and Wilcoxon signed-rank tests. Differences in the magnitude of 173 
cytokine-positive responses between chlamydia-infected cytokine-positive, chlamydia-174 
infected cytokine-negative, and negative control groups were evaluated with the 175 
Wilcoxon rank sum test. Associations of subjects’ demographical or clinical 176 
characteristics with specific cytokines responses were evaluated with the Pearson’s chi-177 
square, Fisher’s exact, or Wilcoxon rank sum tests as appropriate. Differences were 178 
considered significant at a P-value <0.05.  179 
 180 
RESULTS 181 
Ninety women with chlamydia infection at the time of enrollment were investigated in 182 
this study (Table 1). The median age was 21 (range 16 – 32), 97% were African 183 
American, and 1% were Hispanic. 54% of women were asymptomatic and 40% were 184 
diagnosed with co-infections bacterial vaginosis, trichomoniasis, or vaginal candidiasis.  185 
57% of women had a prior history of chlamydia, based on self-report and/or 186 
documentation of prior positive chlamydia test results.  187 
Of the three Th1 cytokines tested, the predominant CD4+ cytokine elicited by 188 
stimulated PBMCs from chlamydia-infected women was TNF-α, not IFN-γ. Fig. 1A 189 
shows the gating scheme utilized for the analyses of CD4+ T-cells from a representative 190 
chlamydia-infected subject showing Pgp3-stimulated flow cytometry plots. CD8+ T-cells 191 
were gated similarly. A CD4+ TNF-α response comprised the majority of C. trachomatis-192 
specific CD4+ Th1 cytokine responses to any antigen, with 79% of women mounting a 193 
positive CD4+ TNF-α response to at least one antigen, compared to 16% and 12% of 194 
women having a CD4+ IFN-γ or IL-2 response, respectively (Fig. 1B, P <0.001). There 195 
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was no difference in the proportion of women with a positive CD4+ IFN-γ vs. IL-2 196 
response. CD8+ T-cell IFN-γ, TNF-α, and IL-2 responses occurred less frequently than 197 
CD4+ Th1 cytokine responses, with 19-28% of subjects’ CD8+ T-cells eliciting a positive 198 
cytokine response for any cytokine to at least one antigen (Fig. 1C). There was no 199 
difference in the proportion of women with a positive CD8+ IFN-γ, TNF-α, or IL-2 200 
response.  201 
We further investigated whether a positive response for any of the CD4+ Th1 202 
cytokines was associated with demographical or clinical characteristics of subjects, 203 
especially age and history of prior chlamydia, as both have been found to be associated 204 
with a reduced risk of reinfection (23, 30). There were no significant associations found 205 
between CD4+ Th1 cytokine responses and age, symptom status, prior history of 206 
chlamydia, number of sexual partners, hormonal contraception, cervicitis, or co-207 
infections (data not shown). 208 
The proportion of women with a positive cytokine response varied with the C. 209 
trachomatis antigen used for stimulation. Stratifying the ICS responses by C. 210 
trachomatis antigens used for stimulating PBMCs, we assessed whether there was a 211 
difference in the proportion of women with a positive cytokine response elicited by 212 
different C. trachomatis antigens. Fig. 2A shows representative flow cytometry plots for 213 
a chlamydia-infected subject and a chlamydia-negative control subject. As shown in Fig. 214 
2B, all three antigens generated predominantly CD4+ TNF-α qualitative responses, but 215 
these responses were most often generated with Pgp3 stimulation when compared with 216 
stimulation with MOMP (64% vs. 34%; P <0.001) or EB (64% vs. 51%; P = 0.035). The 217 
proportion of women with a positive CD4+ TNF-α response to EB was significantly 218 
higher than to MOMP (51% vs. 34%; P = 0.011). There was no significant difference in 219 
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the proportion of women with a positive CD4+ IFN-γ or IL-2 response between the 220 
antigens. In contrast to CD4+ responses, the proportion of women with positive CD8+ 221 
IFN-γ, TNF-α, or IL-2 responses across different antigens was lower, occurring in 6-15% 222 
of women (Fig 2C). The proportion of women with a positive CD8+ IFN-γ response when 223 
stimulated with Pgp3 was significantly lower compared with EB (6% vs. 14%; P = 0.02), 224 
otherwise there was no significant difference in the proportion of women with positive 225 
CD8+ cytokines responses between the antigens.  226 
In subjects with a positive Th1 cytokine response, a higher magnitude of TNF-227 
α- and IFN-γ-producing CD4+ T-cells was seen to all antigens, with Pgp3 eliciting 228 
the highest magnitude of TNF-α-producing CD4+ T cells. Although we expected an 229 
increase in the number of cytokine-producing CD4+ T-cells in subjects with positive 230 
cytokine responses to the various antigens when compared to cytokine-negative 231 
chlamydia-infected women (based on our qualitative analysis cutoff described in the 232 
methods), we wanted to compare the magnitudes of those responses. To evaluate the 233 
differences in the magnitudes (measured by percent cytokine-positive cells) of the 234 
responses between these two group of women and chlamydia-negative controls (all 235 
who had a negative response for all Th1 cytokines we tested), we stratified the data into 236 
chlamydia-infected cytokine positive, chlamydia-infected cytokine negative, and 237 
chlamydia-negative control groups. Given the low proportion of women with positive 238 
CD8+ cytokine responses, we focused our quantification analyses of cytokine producing 239 
cells on CD4+ T-cells. As shown in Fig. 3, comparison of the magnitude of the cytokine-240 
positive CD4+ responses between antigens showed that Pgp3 elicited a 40% higher 241 
CD4+ TNF-α response (median TNF-α-producing cells 0.11%) than MOMP or EB 242 
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(0.08% for both, P = 0.0017 and P = 0.0016, respectively). IFN-γ or IL-2 CD4+ cytokine 243 
positive responses were not significantly different between antigens.  244 
Comparing the magnitude of the cytokine responses in cytokine-positive chlamydia-245 
infected women to either cytokine-negative chlamydia-infected women or chlamydia-246 
negative control women for each antigen, we found a significant increase in the 247 
magnitude of TNF-α- and IFN-γ-positive CD4+ T-cell responses for the cytokine-positive 248 
chlamydia-infected women compared to the other groups for each antigen, but there 249 
was no difference in the magnitude of the IL-2 responses between the groups. The 250 
median TNF-α-positive CD4+ cell responses ranged from 0.080-0.11% in cytokine-251 
positive chlamydia-infected women vs. 0.010-0.015% in cytokine-negative chlamydia-252 
infected women. The median IFN-γ-positive CD4+ cell response ranged from 0.043-253 
0.053% in cytokine-positive chlamydia-infected women vs. 0.000-0.004% in cytokine-254 
negative chlamydia-infected women. There was no difference in the magnitude of the 255 
cytokine responses between cytokine-negative chlamydia-infected women and 256 
negative-control women for any of the cytokines with the exception of Pgp3-stimulated 257 
IL-2 responses, which were higher in the control group compared to the chlamydia-258 
infected IL-2-negative group (P = 0.02). Taken together, these data suggest that 259 
responses to chlamydia antigens are chlamydia-specific and demonstrate the 260 
immunogenicity of Pgp3 in generating TNF-α-positive CD4+ T-cell responses. 261 
In TNF-α-positive subjects, the frequency of positive CD4+ TNF-α responses is 262 
highly variable and antigen dependent. In subjects who had a positive CD4+ TNF-α 263 
response, we evaluated the frequency of inter-antigenic TNF-α-positive responses 264 
across each C. trachomatis antigen to determine if the tested antigens generated 265 
isolated responses (i.e. cytokine responses only to that antigen). We had initially 266 
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hypothesized that EB, being a whole C. trachomatis organism, would elicit the greatest 267 
cross-antigenic responses due to a more diverse antigen presentation compared to 268 
either Pgp3 or MOMP. Including only women with a positive CD4+ TNF-α response to 269 
any antigen (n = 71), we saw significant inter-antigenic variability as expected, with 28% 270 
of women mounting TNF-α-positive responses to all three antigens, 21% to Pgp3 only, 271 
13% to EB only, and 3% to MOMP only (Fig. 4).  272 
A subset of stimulated CD4+ T-cells demonstrated dual cytokine responses. 273 
Using dual gating, we determined the proportion of TNF-α-producing CD4+ T-cells that 274 
were dual-positive for either IL-2 or IFN-γ. Representative dual-gated flow cytometry 275 
plots are shown in Fig. 5A. As shown in Fig. 5B, dual cytokine-positive CD4+ 276 
populations were identified in 28% of subjects with positive TNF-α responses, with TNF-277 
α/IL-2 dual-positive responses being more frequently identified than TNF-α/IFN-γ dual 278 
positive responses (21% vs. 7%, respectively). Corresponding to the immunodominance 279 
observed earlier with Pgp3 eliciting TNF-α responses, Pgp3 elicited a significantly 280 
higher frequency of TNF-α/IL-2 dual-positive responses as compared to MOMP (93% 281 
vs. 20%, respectively; P = 0.003) and EB (93% vs. 27%, respectively; P = 0.002) (Fig. 282 
5C). No significant difference by antigen was identified for TNF-α/IFN-γ responses.  283 
 284 
DISCUSSION 285 
With murine chlamydia models convincingly demonstrating the importance of Th1 286 
CD4+ IFN-γ in chlamydia infection clearance (7) and some animal studies demonstrating 287 
a potential protective role for TNF-α (8, 33), our study sought to increase our 288 
understanding of the frequency and magnitude of C. trachomatis-specific Th1-289 
associated cytokine responses in humans. Using intracellular cytokine staining, we 290 
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analyzed C. trachomatis-specific TNF-α, IFN-γ and IL-2 cytokine production from both 291 
CD4+ and CD8+ T-cells from chlamydia-infected women before treatment. We report for 292 
the first time that the predominant Th1-associated cytokine response in women with 293 
chlamydia was a CD4+ TNF-α response, not IFN-γ, with PBMCs from approximately 294 
80% of women eliciting a CD4+ TNF-α response to at least one of the three C. 295 
trachomatis antigens we tested. Other CD4+ Th1 cytokine responses, IFN-γ and IL-2, 296 
were present, but at much lower frequencies. Also, TNF-α-positive responses had a 297 
higher magnitude than IFN-γ-positive responses, by almost 2-fold.  298 
In contrast to CD4 responses, the overall frequency of CD8+ T-cell TNF-α, IFN-γ and 299 
IL-2 responses were low, occurring in <30% of infected women. Although one might 300 
anticipate low CD8+ responses with the use of a recombinant protein and EBs, we also 301 
observed weak CD8+ responses with the use of five 17-20mer MOMP peptides, which 302 
have been shown to contain strong and functional CD8+ epitopes (45, 46). Further, we 303 
did not see any difference in the response between peptide and protein antigens with 304 
longer incubation time before golgi transport inhibition, which allowed additional time for 305 
antigen processing (data not shown). Therefore, we feel confident that our observed low 306 
CD8+ responses are accurate, though we cannot exclude the possibility that epitopes 307 
not present in our MOMP peptides may contribute to CD8+ responses.  308 
TNF-α is an effector cytokine with known anti-chlamydial activity. In vitro, 309 
recombinant TNF-α alone inhibits C. trachomatis in cell culture (31). C. trachomatis 310 
growth inhibition by TNF-α has been shown to be synergistic with IFN-γ, with a 100-fold 311 
increase in TNF-α potency (31). Inhibition by TNF-α likely occurs by enhancing 312 
mechanisms of IFN-γ-dependent tryptophan depletion, as inhibition can be reversed by 313 
tryptophan supplementation in vitro (32). In animal models, the contribution of TNF-α to 314 
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Chlamydia clearance appears tissue and/or species specific. For example, in the genital 315 
tract, mice and guinea pig studies show increased TNF-α production during chlamydial 316 
infection (15), but the absence of TNF-α does not appear to influence chlamydia 317 
clearance (13, 14). However, in the mouse pneumonitis model, TNF-α inhibition 318 
increased susceptibility to C. muridarum and increased mortality (8). An in vivo study 319 
comparing C. trachomatis and C. muridarum infection of different mouse strains 320 
demonstrated that TNF-α-deficient mice had delayed chlamydia clearance, which 321 
differed by Chlamydia species (33). This may explain the variation in the influence of 322 
TNF-α on Chlamydia growth inhibition and highlights the importance of human studies 323 
for understanding mechanisms of chlamydia clearance.  324 
Our finding that TNF-α is the predominant cytokine elicited to the intracellular 325 
pathogen C. trachomatis suggests it may be an important component of the systemic 326 
effector immune response and is consistent with other studies showing it contributes to 327 
the immune response to C. trachomatis. For example, in individuals with trachoma, 328 
sequence variation associated with the TNF locus has been associated with increased 329 
risk of trachomatous scarring and trichiasis and elevated TNF responses induced by 330 
EBs (34). The presence of the TNF-α-308A allele has been associated with an 331 
increased risk of scarring trachoma (35) and development of severe adhesions in tubal 332 
factor infertility caused by C. trachomatis (36). These studies suggest that although 333 
TNF-α is an effector cytokine that may contribute to protective immune responses, 334 
excess levels of this proinflammatory cytokine can lead to immunopathology after 335 
infection (12, 37). Other evidence supporting the importance of TNF-α in immune 336 
control of intracellular organisms includes studies demonstrating that TNF-α-inhibitory 337 
monoclonal antibodies are strongly associated with an increased susceptibility to 338 
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infection with the intracellular pathogens Histoplasma and Listeria and reactivation of 339 
latent tuberculosis (38). Whether TNF-α is associated with a reduced risk for C. 340 
trachomatis reinfection remains unknown, and we are conducting studies that will 341 
address this important question.  342 
Our finding that positive Th1 cytokine responses, especially IFN-γ, are not generated 343 
in all chlamydia-infected women is consistent with other studies. Two previous human 344 
studies evaluated the frequency of positive IFN-γ responses with PBMC stimulation with 345 
C. trachomatis antigens, measured by either ELISpot or ELISA, but did not evaluate the 346 
frequency of other Th1 cytokine responses including TNF-α (26, 27). In a cohort of 347 
commercial sex workers at risk for C. trachomatis infection, Cohen et al. reported 348 
positive IFN-γ responses to EB occurred in 40% (26). In a cohort of female adolescents 349 
with current or prior C. trachomatis infection, Barral et al. reported positive IFN-γ 350 
responses to EB and MOMP occurred in 62% and 38% of adolescents, respectively 351 
(27). In our study, we used ICS rather than ELISpot or ELISA to characterize cytokines 352 
responses, which allowed us to determine IFN-γ responses produced specifically by 353 
CD4+ and CD8+ T-cells. In our cohort of chlamydia-infected women, a positive CD4+ 354 
IFN-γ response to any of the 3 antigens occurred in 16% of subjects and positive CD8+ 355 
IFN-γ response in 22% of subjects. Our lower frequency of positive IFN-γ responses 356 
compared with the above studies could, in part, reflect differences in assay cutoff for 357 
positivity (with all the studies using different assays) or the fact that we measured IFN-γ 358 
produced specifically by CD4+ and CD8+ cells, whereas the above studies likely 359 
measured IFN-γ production from all CD3+ T-cells with an unknown contribution from 360 
other mononuclear cells (e.g., NK cells, monocytes, etc); it is worth noting that the 361 
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Barral et al. study did partially deplete CD8+ cells to limit detection of IFN-γ from that cell 362 
source (27), though other mononuclear cells remained present.   363 
Murine studies have revealed that TNF-α can act in synergy with other cytokines, 364 
including IL-22 (17) and IFN-γ (16), to modulate the immune response, and the 365 
presence of dual-positive TNF-α/IFN-γ CD4+ T-cell responses in mice correlates with 366 
protection against chlamydia challenge (16). In our study, we found that one third of 367 
TNF-α-positive CD4+ T-cells were able to produce two cytokines, with the majority co-368 
producing IL-2 rather than IFN-γ. IL-2, a pro-survival cytokine, is known to positively 369 
modulate TNF-α production (39). IL-2 also has an important role in lymphocyte 370 
proliferation and arming effector T-cells, as well as maintaining effector T-cells in the 371 
circulation (40). Goon et al. reported a higher frequency of TNF-α/IL-2 dual producing 372 
CD4+ T-cells in patients with HTLV-1-associated pathology than asymptomatic carriers 373 
with similar viral load (41). Their observation raises an interesting question about the 374 
role of TNF-α/IL-2 dual producing CD4+ T-cells in C. trachomatis infection; it would be 375 
important to determine whether these dual cytokine-producing CD4+ T-cells contribute 376 
to immune protection or pathology. 377 
Our study used a panel of multiple C. trachomatis antigens to provide a more 378 
comprehensive characterization of C. trachomatis-specific T-cell responses. We found 379 
that Pgp3 most often elicited a positive CD4+ TNF-α-positive response compared with 380 
the other antigens and also more often elicited dual-positive CD4+ cytokine responses. 381 
To our knowledge, Pgp3 has never been investigated in prior studies of C. trachomatis-382 
specific cytokine cellular immune responses in humans, although it has been 383 
demonstrated in a murine model that Pgp3 deficiency significantly attenuates infectivity 384 
and pathogenicity of C. trachomatis (42). In our study, both single- and dual-positive 385 
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TNF-α-producing CD4+ T-cell responses to Pgp3 were higher in frequency and 386 
magnitude than to MOMP or EB, the latter which contains, as part of its surface, the 387 
chlamydial outer membrane complex comprised of over 300 different proteins (43). 388 
Although it remains unclear why EB did not elicit cytokine responses as frequently as 389 
Pgp3, it could indicate that the key EB antigenic T-cell epitopes are relatively diluted as 390 
compared to a single protein like Pgp3, which thereby may blunt the magnitude of the 391 
immune response. Although an insufficient EB concentration is another possibility, we 392 
think this is unlikely as we used a 4-fold higher concentration of EB in our ICS assays 393 
than Barral et al. (27) and we found that EBs generally elicited more frequent CD4+ 394 
TNF-α responses than MOMP and comparable IFN-γ responses (Fig. 2B-C). Although 395 
the difference in percent positive cells elicited by Pgp3 stimulation versus the other 396 
antigens may appear insignificant (0.11% versus 0.08%), that represents an 397 
approximate 40% increase in circulating TNF-α-positive CD4+ T-cells and a magnitude 398 
of 0.1% is consistent with CD4+ T-cell responses reported by others in post-vaccinated 399 
subjects vaccinated with Hepatitis B (47), influenza (48), and MMR (49).  Additionally, 400 
the observation that Pgp3 generated more dual-positive responses than MOMP or EB 401 
may be an important observation for Pgp3 vaccine candidacy since TNF-α/IFN-γ dual-402 
positive responses have been shown to be functionally superior and elicit protective 403 
responses in murine models (16). 404 
Our study had strengths and limitations. This is the largest study investigating 405 
human C. trachomatis-specific T-cell responses using ICS; a previous study by Miguel 406 
et al that used ICS only studied cytokine responses in 14 C. trachomatis-infected 407 
women and did not present data on the proportion of women with a positive response 408 
(44). Because we included multiple C. trachomatis antigens in our ICS studies, we 409 
were able to investigate inter-antigenic variation of cytokine responses, which revealed 410 
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significant variability in CD4+ TNF-α responses. Our study is the first to evaluate C. 411 
trachomatis-specific cellular immune responses through incorporation of dual gating 412 
into our ICS methodology, which allowed us to differentiate single cytokine producing 413 
cells from dual producing cells. One notable caveat with our findings is that the majority 414 
of subjects studied were African American, representative of the race/ethnicity of the 415 
clinic population, and therefore these findings may not be generalizable to other 416 
populations. In this study, we focused on Th1 cytokine responses, which was the aim 417 
of our initial investigation into C. trachomatis-specific immune responses in humans 418 
because of animal models demonstrating the importance of Th1 responses (7). In 419 
future studies, we will be evaluating a broader group of cytokines, including Th2-420 
associated cytokines, and will evaluate immune responses at follow-up visits to 421 
determine longevity of C. trachomatis-specific immune responses and association of 422 
cytokine responses (single and dual-functional) with chlamydia reinfection. Ultimately, 423 
we hope to identify immune correlates of protection to C. trachomatis infection in 424 
humans.  425 
In summary, the predominate Th1-associated cytokine response in women with 426 
uncomplicated chlamydia was a CD4+ TNF-α response, and CD4+ T-cells producing 427 
both TNF-α and IL-2 were not uncommon. The frequency of CD4+ TNF-α responses 428 
was influenced by antigen used for stimulating PBMCs, with Pgp3 most often eliciting a 429 
CD4+ TNF-α single and dual-positive response. 430 
 431 
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FIGURE LEGENDS 595 
FIG. 1. Intracellular cytokine staining of PBMCs from chlamydia-infected women that were 596 
stimulated with C. trachomatis antigens. PBMCs from 90 chlamydia-infected women were 597 
stimulated with C. trachomatis MOMP peptides, Pgp3, and EB and production of TNF-α, IFN-γ, 598 
and IL-2 was measured by intracellular cytokine staining. (A) Representative flow cytometry 599 
plots showing intracellular cytokine staining gating strategy for CD4+ T-cells producing TNF-α, 600 
IFN-γ, or IL-2. Numbers indicate the percentage of gated cells. CD8+ T-cells were gated 601 
similarly. Fig. 1B and 1C shows the proportion of women with a positive CD4+ or CD8+ T-cell 602 
cytokine response against at least one antigen. A positive cytokine response was defined as  603 
>0.05% and twice the background (media + co-stimulatory antibodies). Significance was 604 
evaluated by the McNemar's chi-square test. 605 
 606 
FIG. 2. The percentage of chlamydia-infected women with a positive Th1 cytokine response 607 
based on the C. trachomatis antigen used for stimulating PBMCs. (A) Representative flow 608 
cytometry plots from intracellular cytokine staining of CD4+ T-cells from a chlamydia-negative 609 
and chlamydia-infected subject. (B, C) Percentage of women with a positive cytokine response 610 
to chlamydia antigens in CD4+ and CD8+ T-cells. A positive cytokine response was defined as  611 
>0.05% and twice the background (media + co-stimulatory antibodies). Significance was 612 
determined using McNemar's chi-square test. 613 
 614 
FIG. 3. Magnitude of cytokine responses from CD4+ T-cells stimulated with C. trachomatis 615 
antigens in chlamydia-infected women with a positive or negative cytokine response 616 
(qualitative) and in chlamydia-negative control women. Responses were measured by 617 
intracellular cytokine staining. A positive cytokine response was defined as >0.05% and twice 618 
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the background (media + co-stimulatory antibodies). The magnitude of the cytokine response is 619 
shown as percentage of total CD4+ T-cells after subtracting the background response, stratified 620 
by C. trachomatis antigen used. The box denotes the interquartile range and the whiskers 621 
denote the 5th and 95th percentiles. Dots denote outliers. The median is shown as the horizontal 622 
line in the box. N denotes the number of subjects. Significance was evaluated by Wilcoxon 623 
signed-rank or rank sum tests. The asterisks denote P <0.001. The Y-axis is log10. 624 
 625 
FIG. 4. Venn diagram demonstrating the overlap of CD4+ TNF-α responses across C. 626 
trachomatis antigens used for PBMC stimulation. Subjects with a positive CD4+ TNF-α 627 
response to any antigen were identified (n = 71) and the concordance of positive responses 628 
across antigens MOMP, Pgp3, and EB was evaluated. The percentages indicate the proportion 629 
of total positive CD4+ TNF-α responses elicited by antigen(s). 630 
 631 
FIG. 5. Dual cytokine-producing CD4+ T-cells from chlamydia-infected women expressing TNF-632 
α and either IL-2 or IFN-γ. (A) Representative flow cytometry plots from chlamydia-infected 633 
women with dual-positive CD4+ TNF-α and either IFN-γ or IL-2 responses. (B) Pie chart 634 
showing proportion of positive CD4+ TNF-α responses that produced TNF-α alone or produced 635 
both TNF-α and IL-2 responses or both TNF-α and IFN-γ responses. (C) Percentage of total 636 
dual-positive subjects with a dual positive cytokine response by antigen. n = 15 for a positive 637 
CD4+ TNF-α+/IL-2+ response to at least one antigen and n = 5 for a positive CD4+ TNF-α+/IFN-638 
γ+ response to at least one antigen. A positive cytokine response was defined as >0.05% and 639 
twice the background (media + co-stimulatory antibodies). The number of positive responses by 640 
antigen is indicated above each bar. Significance was determined using McNemar's chi-square 641 
test.  642 
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Column2 Column3 Table	1.	Study	Subject	Characteristics	(n=	90)
Subject	Characteristics n	 (%)
		Median	age	(range) 22	(16-32)
		Race
							Black 87	(97)
							White 3	(3)
		Ethnicity
							Non-Hispanic 89	(99)
							Hispanic 1	(1)
		Hormonal	contraception 41	(46)
		Median	prior	sex	partners**
					Last	3	mo.	(range) 1	(1-5)
		Prior	Chlamydia* 51	(57)
		Asymptomatic 49	(54)
		Cervicitis* 17	(19)
		Co-Infections
							HIV	infection 0
							Gonorrhea 0
							Bacterial	Vaginosis 26	(29)
							Trichomoniasis 3	(3)
							Candidiasis 11	(12)
*	n =89,	**n =88
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